Previous 10 | Next 10 |
SAN CARLOS, Calif., Aug. 02, 2023 (GLOBE NEWSWIRE) -- Allakos Inc. (Nasdaq: ALLK), a clinical-stage biotechnology company developing therapeutics which target immunomodulatory receptors present on immune effector cells involved in allergy, inflammatory and proliferative diseases, today announced ...
– AK006 inhibits IgE mediated mast cell activation and shows similar IgE inhibitory activity as remibrutinib – – AK006 also inhibits non-IgE mast cell activation pathways, including KIT-mediated activation– SAN CARLOS, Calif., June 12, 2023 (GLOBE NEWSWIRE) -- Al...
SAN CARLOS, Calif., June 05, 2023 (GLOBE NEWSWIRE) -- Allakos Inc. (Nasdaq: ALLK), a clinical-stage biotechnology company developing therapeutics which target immunomodulatory receptors present on immune effector cells involved in allergy, inflammatory and proliferative diseases, today announced ...
2023-05-12 17:00:53 ET Allakos (NASDAQ: ALLK) finished the trading week in style, with its stock price climbing by just under 9% on Friday. That was largely due to an analyst recommendation upgrade, which, in turn, was encouraged by strong quarterly results posted by the company. In...
2023-05-12 09:15:18 ET Allakos ( NASDAQ: ALLK ) rose ~8% pre-market Friday after Jefferies upgraded the immunology-focused biotech to Buy from Hold, citing an attractive risk-reward setup ahead of a Phase 2 readout for its lead candidate lirentelimab. San Carlos, California-...
2023-05-09 17:56:54 ET Allakos press release ( NASDAQ: ALLK ): Q1 GAAP EPS of -$0.49. For further details see: Allakos GAAP EPS of -$0.49
SAN CARLOS, Calif., May 09, 2023 (GLOBE NEWSWIRE) -- Allakos Inc. (the “Company”) (Nasdaq: ALLK), a biotechnology company developing antibodies for the treatment of allergic, inflammatory and proliferative diseases, today provided a business update and reported financial results for...
2023-04-10 17:30:11 ET Gainers: Nogin ( NOGN ) +18% . Allakos ( ALLK ) +5% . TPI Composites ( TPIC ) +5% . SMART Global Holdings ( SGH ) +3% . PriceSmart ( PSMT ) +3% . Losers: NVIDIA ( NVDA ) -26% . Kur...
2023-03-07 16:05:58 ET Shares of the clinical-stage biopharma Allakos (NASDAQ: ALLK) defied the turbulence in the broader markets today. Specifically, the drugmaker's shares were up by a healthy 21% on heavy volume at Tuesday's close. The big gain came in response to the company...
2023-03-07 12:39:41 ET Gainers: ThredUp ( TDUP ) +73% . WW International ( WW ) +49% . Unicycive ( UNCY ) +39% . Protagonist Therapeutics ( PTGX ) +32% . Bionomics ( BNOX ) +28% . Novo Integrated Sciences ( NVOS ) +25% ...
News, Short Squeeze, Breakout and More Instantly...
– AK006 achieved serum concentrations consistent with levels demonstrating inhibitory activity in preclinical experiments – – Skin biopsies from subjects treated with AK006 show high receptor occupancy – – AK006 was well-tolerated with a favorable safety pro...
– Top-line Phase 1 CSU results expected at year end 2024 – SAN CARLOS, Calif., May 28, 2024 (GLOBE NEWSWIRE) -- Allakos Inc. (Nasdaq: ALLK), a biotechnology company developing AK006 for the treatment of mast cell-driven diseases, today announced that the first patient with chr...
SAN CARLOS, Calif., May 09, 2024 (GLOBE NEWSWIRE) -- Allakos Inc. (the “Company”) (Nasdaq: ALLK), a biotechnology company developing antibodies for the treatment of allergic, inflammatory and proliferative diseases, today provided a business update and reported financial results for...